The clinical value of clinical treatment score post-5 years in patients with premenopausal breast cancer: a retrospective analysis of ASTRRA trial
Yireh Han, Hee Jeong Kim, Soo Yeon Baek, Sei-Hyun Ahn et autres
BACKGROUND: The Clinical Treatment Score post-5 years (CTS5), a prognostic tool for late distant recurrence, was validated in postmenopausal patients, but its value in premenopausal women remains unclear. Using 8-year ASTRRA data, we evaluated the prognostic performance of CTS5 in premenopausal breast …
kr (code pays fourni par la source)
0 citations
The Breast